50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,660.72 (-0.88%)
DOW   29,308.47 (-0.95%)
QQQ   274.55 (-0.35%)
AAPL   150.64 (+0.14%)
MSFT   238.04 (+0.05%)
META   137.10 (-2.36%)
GOOGL   98.02 (-0.73%)
AMZN   114.87 (+0.96%)
TSLA   275.95 (+0.23%)
NVDA   122.82 (-1.87%)
NIO   17.62 (-0.11%)
BABA   79.22 (+0.53%)
AMD   66.52 (-2.12%)
T   15.73 (-1.75%)
MU   48.88 (-2.44%)
CGC   2.76 (-2.82%)
F   12.02 (-2.36%)
GE   65.03 (+0.74%)
DIS   98.32 (-1.19%)
AMC   7.37 (-7.76%)
PYPL   85.11 (-2.14%)
PFE   43.92 (-0.36%)
NFLX   224.02 (-1.06%)
S&P 500   3,660.72 (-0.88%)
DOW   29,308.47 (-0.95%)
QQQ   274.55 (-0.35%)
AAPL   150.64 (+0.14%)
MSFT   238.04 (+0.05%)
META   137.10 (-2.36%)
GOOGL   98.02 (-0.73%)
AMZN   114.87 (+0.96%)
TSLA   275.95 (+0.23%)
NVDA   122.82 (-1.87%)
NIO   17.62 (-0.11%)
BABA   79.22 (+0.53%)
AMD   66.52 (-2.12%)
T   15.73 (-1.75%)
MU   48.88 (-2.44%)
CGC   2.76 (-2.82%)
F   12.02 (-2.36%)
GE   65.03 (+0.74%)
DIS   98.32 (-1.19%)
AMC   7.37 (-7.76%)
PYPL   85.11 (-2.14%)
PFE   43.92 (-0.36%)
NFLX   224.02 (-1.06%)
S&P 500   3,660.72 (-0.88%)
DOW   29,308.47 (-0.95%)
QQQ   274.55 (-0.35%)
AAPL   150.64 (+0.14%)
MSFT   238.04 (+0.05%)
META   137.10 (-2.36%)
GOOGL   98.02 (-0.73%)
AMZN   114.87 (+0.96%)
TSLA   275.95 (+0.23%)
NVDA   122.82 (-1.87%)
NIO   17.62 (-0.11%)
BABA   79.22 (+0.53%)
AMD   66.52 (-2.12%)
T   15.73 (-1.75%)
MU   48.88 (-2.44%)
CGC   2.76 (-2.82%)
F   12.02 (-2.36%)
GE   65.03 (+0.74%)
DIS   98.32 (-1.19%)
AMC   7.37 (-7.76%)
PYPL   85.11 (-2.14%)
PFE   43.92 (-0.36%)
NFLX   224.02 (-1.06%)
S&P 500   3,660.72 (-0.88%)
DOW   29,308.47 (-0.95%)
QQQ   274.55 (-0.35%)
AAPL   150.64 (+0.14%)
MSFT   238.04 (+0.05%)
META   137.10 (-2.36%)
GOOGL   98.02 (-0.73%)
AMZN   114.87 (+0.96%)
TSLA   275.95 (+0.23%)
NVDA   122.82 (-1.87%)
NIO   17.62 (-0.11%)
BABA   79.22 (+0.53%)
AMD   66.52 (-2.12%)
T   15.73 (-1.75%)
MU   48.88 (-2.44%)
CGC   2.76 (-2.82%)
F   12.02 (-2.36%)
GE   65.03 (+0.74%)
DIS   98.32 (-1.19%)
AMC   7.37 (-7.76%)
PYPL   85.11 (-2.14%)
PFE   43.92 (-0.36%)
NFLX   224.02 (-1.06%)
NASDAQ:VCYT

Veracyte - VCYT Stock Forecast, Price & News

$16.81
+0.23 (+1.39%)
(As of 09/26/2022 12:33 PM ET)
Add
Compare
Today's Range
$16.45
$17.27
50-Day Range
$16.58
$27.90
52-Week Range
$14.85
$54.13
Volume
26,886 shs
Average Volume
942,499 shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.50

Veracyte MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
152.5% Upside
$42.50 Price Target
Short Interest
Healthy
4.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.05
Upright™ Environmental Score
News Sentiment
0.10mentions of Veracyte in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.80) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

305th out of 1,069 stocks

Medical Laboratories Industry

12th out of 27 stocks

VCYT stock logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

3 Cathie Wood Stocks for the Future - Nasdaq
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings
8/02/2022
Today
9/26/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
761
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.50
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+152.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-75,560,000.00
Pretax Margin
-18.97%

Debt

Sales & Book Value

Annual Sales
$219.51 million
Book Value
$15.43 per share

Miscellaneous

Free Float
69,500,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
1.17

Key Executives

  • Ms. Bonnie H. AndersonMs. Bonnie H. Anderson (Age 64)
    Co-Founder & Exec. Chairwoman
    Comp: $1.21M
  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 52)
    CEO & Director
    Comp: $900.4k
  • Ms. Rebecca ChambersMs. Rebecca Chambers (Age 44)
    Exec. VP & CFO
    Comp: $607.65k
  • Dr. Giulia C. Kennedy Ph.D. (Age 63)
    Global Chief Scientific Officer & Chief Medical Officer
    Comp: $691.33k
  • Dr. Tina S. Nova Ph.D. (Age 68)
    Pres of CLIA U.S. Bus.
    Comp: $4.58k
  • Ms. Beverly Jane Alley CPA (Age 59)
    VP & Corp. Controller
    Comp: $398.01k
  • Mr. Jonathan Wygant (Age 51)
    VP & Chief Accounting Officer
  • Ms. Annie McGuire (Age 42)
    Sr. VP & Gen. Counsel
  • Ms. Tracy Morris
    VP of Global Corp. Communications
  • Mr. John Walter Hanna Jr. (Age 41)
    Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma













VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price forecast for 2022?

6 equities research analysts have issued 12-month price objectives for Veracyte's stock. Their VCYT share price forecasts range from $31.00 to $59.00. On average, they expect the company's stock price to reach $42.50 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2022?

Veracyte's stock was trading at $41.20 at the beginning of 2022. Since then, VCYT stock has decreased by 59.2% and is now trading at $16.82.
View the best growth stocks for 2022 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings results on Tuesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The biotechnology company had revenue of $72.86 million for the quarter, compared to the consensus estimate of $67.37 million. Veracyte had a negative net margin of 18.13% and a negative trailing twelve-month return on equity of 4.05%.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $272.00 million-$280.00 million, compared to the consensus revenue estimate of $272.42 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.40%), State Street Corp (7.19%), Artisan Partners Limited Partnership (5.37%), Sumitomo Mitsui Trust Holdings Inc. (4.09%), Nikko Asset Management Americas Inc. (4.09%) and Pictet Asset Management SA (2.02%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho and Robert S Epstein.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $16.82.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.20 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Veracyte have?

The company employs 761 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.